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Diastolic Heart Failure – Innovative Extra and Intra Ventricular Solutions
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1CorAssist CardioVascular, Herzliya, Israel; 2Duke University Medical Center/Duke
Clinical Research Institute, Durham, NC
Background: Diastolic heart failure (DHF) accounts for over 40% of HF cases. Proven
evidence based treatment is lacking. A novel mechanical approach, utilizing energy
exerted by the left ventricle (LV) during systole and returning it to the ventricle during
diastole to enhance diastolic performance, was realized in two approachs: An Extra-
ventricular device (ImCardia™), comprised of elastic springs attached to the LV
epimyocardium. A trans apically delivered Intra-ventricular device (CORolla™)
comprised of a three-arms spring.
Methods: The ImCardia™ device was implanted as an add-on to AVR (study group,
n=10), and compared to AVR only (control group, N=9). The patients were followed
up to 24 months to examine indications of safety and efficacy. The CORolla™ device
was implanted off-pump in trans-apical approach in healthy sheep (N=26). The sheep
were followed up to 9 months. Device acute and chronic safety was evaluated.
Results: ImCardia™: During follow-up period there were no device-related
complications or adverse events. Improvement in NYHA functional class, 6-minute
walk test and quality of life were similar for both groups. LV mass regression after 18-
24 months: -90 gr ± 82 gr in control group Vs -126 gr ± 33 gr in study group. Left
atrial area, an important marker of diastolic dysfunction, increased slightly in control
group (+1.5 cm2 ± 4.09 cm2) but decreased in study group (-2.29 cm2 ± 3.09 cm2).
CORolla™: good recuperation post implantation with no weight reduction, no EF
reduction, good device functionality and safety in follow-up up to 9 months.
Conclusion: A passive extra-cardiac device which transfers energy from systole to
diastole, may improve diastolic performance as suggested by further decrease in left
atrial size beyond that expected from AVR only; not only the device did not induce LV
hypertrophy, it rather demonstrated a trend of LV mass regression enhancement. Using
this methodology, an Intra-ventricular elastic device implanted transapically off-pump
demonstrated safe profile. Clinical study is planned to start toward end 2011.
Percutaneous approach for the intra-ventricular device is in R&D process.
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Background: To investigate the potential benefit of Impella 2.5 in high-risk PCI
(HRPCI) compared to the intra-aortic balloon-pump (IABP) in a prospective
multicenter clinical trial.
Methods: The PROTECT II trial was designed to randomize 654 HRPCI patients who
required prophylactic hemodynamic support to Impella or IABP. Patients with 3-vessel
disease and LV ejection fraction (LVEF) ≤30%, or with unprotected left main or last
patent conduit and LVEF ≤35% were eligible for enrollment. Selection of the
revascularization approach was at the discretion of the PCI operator. The primary
endpoint was a composite of 10 major adverse events (MAE) at 30 days with a follow-
up at 90 days.
Results: Enrollment began in late 11/2007 and reached the 50% mark (n=327) by
02/2010. After pre-specified review of the 50% enrollment data, the Data Safety
Monitoring Board recommended termination of the study due to futility on the 30-day
primary analysis. At the time of the recommendation (11/2010), the study had reached
68% of the planned enrollment (N=447). The preliminary analysis showed a significant
learning curve with Impella, with outcomes improving over the course of the trial.
There was a trend for better outcomes at 30 days in favor of Impella for the entire per
protocol population (p=0.10). At the 90-day pre-specified follow-up, there was a
significant reduction in MAE in favor of Impella (p=0.03, see Figure). The final new
clinical and angiographic results of the entire cohort will be presented.
Conclusion: PROTECT II was terminated early on assumptions based on the first half
of the data. The analysis of the full cohort provides more insight into the study and
suggests positive outcomes over time for the Impella compared to the IABP with a
similar safety profile.
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Is It Appropriate To Take All Post-Resuscitation Patients Suspected of Having
an Acute MI For Urgent Angiography?
Vivek K Reddy, Vinay R Hosmane, Andrew Doorey, William S Weintraub, Ehsanur
Rahman
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Background: Recent studies of patients who have been resuscitated from out-of-
hospital cardiac arrest (OHCA) have shown increasing benefit from timely reperfusion
therapy for those with STEMI as the etiology. Though no randomized trials have been
performed, patients with OHCA with early reperfusion for concurrent STEMI have a
mean survival rate of 65%, compared to historical survival of only 25% to 35% for
those with only OHCA. The addition of early hypothermia to early reperfusion results
in significantly improved neurological function. We reviewed our data to see if OHCA
patients who do not fit these criteria were undergoing urgent angiography
inappropriately.
Methods: Our facility is a large, academic, community center with around-the-clock
catheterization capabilities for STEMI. We retrospectively examined our internal
databases of consecutive patients suspected of having STEMI between January 1, 2001
and December 31, 2010. Further data was obtained from electronic hospital records,
emergency department records, paramedic records, and the cardiac catheterization
database.
Results: Between January 1, 2001 and December 31, 2010, there were 3908
consecutive patients who were suspected of having an MI, 409 of which required CPR.
Of these, 240 underwent emergent angiography. In 191 patients a culprit lesion was
identified, but in 49 (20%) no culprit lesion was seen. Review of the pre-cath EKGs
showed no definitive ST-elevation in 26 of 49 patients (53%). Ventricular fibrillation
or tachycardia was the presenting rhythm in 34 patients (69%). During their
hospitalization, 26 patients (53%) died.
Conclusion: Even though the favorable outcomes in the available literature are based
on STEMI concurrent with OHCA, a significant number of patients who do not have
ST-elevation on post-resuscitation EKG are undergoing cardiac angiography
emergently. Other measures such as stabilizing hemodynamics, controlling rhythms,
and, perhaps most importantly, early initiation of hypothermia are probably more
important at this stage when the EKG does not show ST-elevation.
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Background: Clinical outcomes and cost-effectiveness of new technologies for
hemodynamic support in patients with left ventricular dysfunction and complex
anatomy have not been previously studied.
Methods: PROTECT II studied patients with 3 vessel disease and LV ejection fraction
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